Last reviewed · How we verify

Duodenal Ulcer due to H. Pylori — Treatment Landscape & Competitive Intelligence

Duodenal Ulcer due to H. Pylori (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Duodenal Ulcer due to H. Pylori, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Aciphex rabeprazole Waylis Proton Pump Inhibitor Potassium-transporting ATPase 1999-01-01
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Biaxin clarithromycin Generic (originally Abbott/AbbVie) Macrolide Antimicrobial [EPC] Potassium voltage-gated channel subfamily H member 2 1991-10-31
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01
Amoxil amoxicillin Generic (originally Beecham/GSK) Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Metro I.V. In Plastic Container METRONIDAZOLE Baxter Nitroimidazole Antimicrobial [EPC] 1963-01-01
Pepto-Bismol bismuth subsalicylate Generic (Procter & Gamble) Bismuth [EPC] Cyclooxygenase 1939-01-01
Aciphex Aciphex University of Utah Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Duodenal Ulcer due to H. Pylori
  2. AstraZeneca · 1 drug in Duodenal Ulcer due to H. Pylori
  3. AstraZeneca (originally Astra AB) · 1 drug in Duodenal Ulcer due to H. Pylori
  4. Baxter · 1 drug in Duodenal Ulcer due to H. Pylori
  5. GSK (originally Glaxo) · 1 drug in Duodenal Ulcer due to H. Pylori
  6. Generic (Procter & Gamble) · 1 drug in Duodenal Ulcer due to H. Pylori
  7. Generic (originally Abbott/AbbVie) · 1 drug in Duodenal Ulcer due to H. Pylori
  8. Generic (originally Beecham/GSK) · 1 drug in Duodenal Ulcer due to H. Pylori
  9. Generic (originally Takeda) · 1 drug in Duodenal Ulcer due to H. Pylori
  10. Janssen-Cilag, S.A. · 1 drug in Duodenal Ulcer due to H. Pylori
  11. King George's Medical University · 1 drug in Duodenal Ulcer due to H. Pylori
  12. RenJi Hospital · 1 drug in Duodenal Ulcer due to H. Pylori

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Duodenal Ulcer due to H. Pylori:

Cite this brief

Drug Landscape (2026). Duodenal Ulcer due to H. Pylori — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/duodenal-ulcer-due-to-h-pylori. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing